Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Janneke W. de Boer"'
Autor:
Kylie Keijzer, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Gerwin A. Huls, Lisanne V. van Dijk, Tom van Meerten, Anne G. H. Niezink
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV
Externí odkaz:
https://doaj.org/article/4ada8881a9dc4ff2b0f6fbb01bb5e429
Autor:
Kylie Keijzer, Anne G.H. Niezink, Janneke W. de Boer, Jaap A. van Doesum, Walter Noordzij, Tom van Meerten, Lisanne V. van Dijk
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 1102-1114 (2023)
In the treatment of Non-Hodgkin lymphoma (NHL), multiple therapeutic options are available. Improving outcome predictions are essential to optimize treatment. The metabolic active tumor volume (MATV) has shown to be a prognostic factor in NHL. It is
Externí odkaz:
https://doaj.org/article/bdc6202699d644c7810f07582ab8af76
Autor:
Janneke W. de Boer, Kylie Keijzer, Elise R. A. Pennings, Jaap A. van Doesum, Anne M. Spanjaart, Margot Jak, Pim G. N. J. Mutsaers, Suzanne van Dorp, Joost S. P. Vermaat, Marjolein W. M. van der Poel, Lisanne V. van Dijk, Marie José Kersten, Anne G. H. Niezink, Tom van Meerten
Publikováno v:
Cancers, Vol 15, Iss 22, p 5443 (2023)
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL). To assess the risk of CRS
Externí odkaz:
https://doaj.org/article/0f75a1ea8c6c4cfe9e62d25b04c5a5f8
Autor:
Anne M. Spanjaart, Elise R. A. Pennings, Pim G. N. J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke W. de Boer, Anne G. H. Niezink, Milan Kos, Joost S. P. Vermaat, Aniko Sijs-Szabo, Marjolein W. M. van der Poel, Inger S. Nijhof, Maria T. Kuipers, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Jeanette K. Doorduijn, Yasmina I. M. Serroukh, Monique C. Minnema, Tom van Meerten, Marie José Kersten
Publikováno v:
Cancers, Vol 15, Iss 17, p 4334 (2023)
The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique n
Externí odkaz:
https://doaj.org/article/2eadb1bce5144eb5ad3c080c9c142274
Publikováno v:
Diabetic Medicine, 40(2). Wiley